Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nielsen Survey Finds China Consumers Most Concerned About Drugs’ Credibility

This article was originally published in PharmAsia News

Executive Summary

According to a recent worldwide online survey jointly conducted by Nielsen Company and the Association of the European Self-Medication Industry, more than 30 percent of China consumers indicate they would self-medicate for minor ailments such as headache, cold and dyspepsia. They consider credibility, safety and effectiveness as the three most important criteria for OTC drugs. Nearly two-thirds of respondents prefer to take medicine only if they do not get well naturally after some time, while two percent say they never take medicine. Almost 70 percent of these two groups attribute their avoidance of medicine to the perception of drug toxicity. When selecting prescription drugs, close to half of China respondents said that a trustworthy brand is the most important factor. Such concern is also the highest in the global survey. (Click here for more - Chinese Language)

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts